Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
- Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
- Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
- Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
- Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
- Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
- Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
- Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
- Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
- Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.
Revvity Price Performance
Revvity stock traded down $1.14 during mid-day trading on Thursday, hitting $157.11. The company’s stock had a trading volume of 1,467,522 shares, compared to its average volume of 1,543,251. The company has a quick ratio of 2.10, a current ratio of 2.65 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $17.53 billion, a P/E ratio of 69.52, a P/E/G ratio of 2.79 and a beta of 1.08. Revvity Inc. has a twelve month low of $81.22 and a twelve month high of $171.74. The stock’s fifty day moving average price is $150.01 and its two-hundred day moving average price is $114.10.
Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.08. The firm had revenue of $728.90 million during the quarter, compared to analyst estimates of $694.73 million. Revvity had a net margin of 8.61% and a return on equity of 8.64%. The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. Research analysts forecast that Revvity Inc. will post 5.42 earnings per share for the current year.
Revvity Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 22nd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio is currently 12.39%.
Institutional Investors Weigh In On Revvity
Several hedge funds have recently modified their holdings of the business. Apollon Wealth Management LLC lifted its stake in shares of Revvity by 2.7% in the third quarter. Apollon Wealth Management LLC now owns 2,778 shares of the company’s stock valued at $425,000 after buying an additional 73 shares during the period. Moors & Cabot Inc. increased its stake in Revvity by 3.1% during the third quarter. Moors & Cabot Inc. now owns 2,448 shares of the company’s stock valued at $374,000 after acquiring an additional 73 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in Revvity by 5.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company’s stock valued at $231,000 after acquiring an additional 106 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Revvity by 17.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock valued at $66,000 after acquiring an additional 109 shares in the last quarter. Finally, Angeles Wealth Management LLC raised its holdings in Revvity by 2.0% in the 2nd quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock valued at $646,000 after acquiring an additional 112 shares in the last quarter. 86.65% of the stock is owned by institutional investors.
Insider Buying and Selling
In other Revvity news, insider Tajinder Vohra sold 7,330 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. The trade was a 9.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 9,045 shares of company stock valued at $1,281,439 in the last quarter. Corporate insiders own 0.85% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have commented on RVTY. William Blair assumed coverage on shares of Revvity in a research report on Monday, October 5th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. raised their price target on shares of Revvity from $155.00 to $160.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Barclays lifted their price objective on shares of Revvity from $160.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 4th. Royal Bank Of Canada upped their price objective on shares of Revvity from $135.00 to $172.00 and gave the stock a “sector perform” rating in a report on Wednesday, November 4th. Finally, UBS Group assumed coverage on shares of Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $133.86.
Get Our Latest Analysis on RVTY
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Revvity
Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company’s work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.
Read More
- Five stocks we like better than Revvity
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
